AstraZeneca PLC:s resultatrapport för helåret och fjärde kvartalet 2019

Ett år präglat av betydande innovation för patienter; den strategiska omvandlingen accelererarAstraZeneca har levererat ett år med stark tillväxt, tack vare lanseringen av nya läkemedel[1], ytterligare framsteg i forskningsportföljen och med ett stort antal godkännanden och övergripande resultat. Dessa trender kommer att fortsätta under 2020,…

Fortsätt läsa

AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan

Agreement strengthens AstraZeneca's respiratory and immunology pipelineAstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn's disease (CD)[1] and a Phase IIb trial in ulcerative colitis (UC).[2] AstraZeneca and Allergan will terminate their existing license agreement (https://www.astrazeneca.com/investor-relations/stock-exchange-announcements/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html)…

Fortsätt läsa

AstraZeneca divests rights to established hypertension medicines

Sale of Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma supports AstraZeneca's strategy of focusing on pipeline of new medicinesAstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to…

Fortsätt läsa

Brilinta met primary endpoint in Phase III THALES trial in stroke

Brilinta reduced the risk of the composite of stroke and death after an acute ischaemic stroke or transient ischaemic attackHigh-level results from the Phase III THALES trial showed AstraZeneca's Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant…

Fortsätt läsa